Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 79

1.

Production of E. coli-expressed Self-Assembling Protein Nanoparticles for Vaccines Requiring Trimeric Epitope Presentation.

Karch CP, Burkhard P, Matyas GR, Beck Z.

J Vis Exp. 2019 Aug 21;(150). doi: 10.3791/60103.

PMID:
31498330
2.

Erratum for Ramakrishnan et al., "Enhanced Immunogenicity and Protective Efficacy of a Campylobacter jejuni Conjugate Vaccine Coadministered with Liposomes Containing Monophosphoryl Lipid A and QS-21".

Ramakrishnan A, Schumack NM, Gariepy CL, Eggleston H, Nunez G, Espinoza N, Nieto M, Castillo R, Rojas J, McCoy AJ, Beck Z, Matyas GR, Alving CR, Guerry P, Poly F, Laird RM.

mSphere. 2019 Jun 26;4(3). pii: e00440-19. doi: 10.1128/mSphere.00440-19. No abstract available.

3.

Particle size analyses of polydisperse liposome formulations with a novel multispectral advanced nanoparticle tracking technology.

Singh P, Bodycomb J, Travers B, Tatarkiewicz K, Travers S, Matyas GR, Beck Z.

Int J Pharm. 2019 Jul 20;566:680-686. doi: 10.1016/j.ijpharm.2019.06.013. Epub 2019 Jun 6.

PMID:
31176851
4.

Safety, toxicity and immunogenicity of a malaria vaccine based on the circumsporozoite protein (FMP013) with the adjuvant army liposome formulation containing QS21 (ALFQ).

Cawlfield A, Genito CJ, Beck Z, Bergmann-Leitner ES, Bitzer AA, Soto K, Zou X, Hadiwidjojo SH, Gerbasi RV, Mullins AB, Noe A, Waters NC, Alving CR, Matyas GR, Dutta S.

Vaccine. 2019 Jun 27;37(29):3793-3803. doi: 10.1016/j.vaccine.2019.05.059. Epub 2019 May 28.

5.

Correction for Ramakrishnan et al., "Enhanced Immunogenicity and Protective Efficacy of a Campylobacter jejuni Conjugate Vaccine Coadministered with Liposomes Containing Monophosphoryl Lipid A and QS-21".

Ramakrishnan A, Schumack NM, Gariepy CL, Eggleston H, Nunez G, Espinoza N, Nieto M, Castillo R, Rojas J, McCoy AJ, Beck Z, Matyas GR, Alving CR, Guerry P, Poly F, Laird RM.

mSphere. 2019 May 22;4(3). pii: e00351-19. doi: 10.1128/mSphere.00351-19. No abstract available.

6.

Enhanced Immunogenicity and Protective Efficacy of a Campylobacter jejuni Conjugate Vaccine Coadministered with Liposomes Containing Monophosphoryl Lipid A and QS-21.

Ramakrishnan A, Schumack NM, Gariepy CL, Eggleston H, Nunez G, Espinoza N, Nieto M, Castillo R, Rojas J, McCoy AJ, Beck Z, Matyas GR, Alving CR, Guerry P, Poly F, Laird RM.

mSphere. 2019 May 1;4(3). pii: e00101-19. doi: 10.1128/mSphere.00101-19. Erratum in: mSphere. 2019 May 22;4(3):. mSphere. 2019 Jun 26;4(3):.

7.

Longitudinal Analysis Reveals Early Development of Three MPER-Directed Neutralizing Antibody Lineages from an HIV-1-Infected Individual.

Krebs SJ, Kwon YD, Schramm CA, Law WH, Donofrio G, Zhou KH, Gift S, Dussupt V, Georgiev IS, Schätzle S, McDaniel JR, Lai YT, Sastry M, Zhang B, Jarosinski MC, Ransier A, Chenine AL, Asokan M, Bailer RT, Bose M, Cagigi A, Cale EM, Chuang GY, Darko S, Driscoll JI, Druz A, Gorman J, Laboune F, Louder MK, McKee K, Mendez L, Moody MA, O'Sullivan AM, Owen C, Peng D, Rawi R, Sanders-Buell E, Shen CH, Shiakolas AR, Stephens T, Tsybovsky Y, Tucker C, Verardi R, Wang K, Zhou J, Zhou T, Georgiou G, Alam SM, Haynes BF, Rolland M, Matyas GR, Polonis VR, McDermott AB, Douek DC, Shapiro L, Tovanabutra S, Michael NL, Mascola JR, Robb ML, Kwong PD, Doria-Rose NA.

Immunity. 2019 Mar 19;50(3):677-691.e13. doi: 10.1016/j.immuni.2019.02.008. Epub 2019 Mar 12.

PMID:
30876875
8.

Glycosylation of the HIV-1 Env V1V2 loop to form a native-like structure may not be essential with a nanoparticle vaccine.

Karch CP, Matyas GR, Burkhard P, Beck Z.

Future Virol. 2019 Feb;14(2):51-54. doi: 10.2217/fvl-2018-0174. Epub 2019 Jan 10. No abstract available.

9.

Design and characterization of a self-assembling protein nanoparticle displaying HIV-1 Env V1V2 loop in a native-like trimeric conformation as vaccine antigen.

Karch CP, Bai H, Torres OB, Tucker CA, Michael NL, Matyas GR, Rolland M, Burkhard P, Beck Z.

Nanomedicine. 2019 Feb;16:206-216. doi: 10.1016/j.nano.2018.12.001. Epub 2018 Dec 18.

PMID:
30576800
10.

Saturated phospholipids are required for nano- to micron-size transformation of cholesterol-containing liposomes upon QS21 addition.

Singh P, Beck Z, Matyas GR, Alving CR.

J Liposome Res. 2019 Sep;29(3):247-250. doi: 10.1080/08982104.2018.1538239. Epub 2018 Nov 23.

PMID:
30350748
11.

Self-Assembling Protein Nanoparticles: implications for HIV-1 vaccine development.

Karch CP, Matyas GR, Burkhard P, Beck Z.

Nanomedicine (Lond). 2018 Sep;13(17):2121-2125. doi: 10.2217/nnm-2018-0222. Epub 2018 Oct 1. Review. No abstract available.

12.

Liposome-Encapsulated Human Immunodeficiency Virus-1 gp120 Induces Potent V1V2-Specific Antibodies in Humans.

Rao M, Onkar S, Peachman KK, White Y, Trinh HV, Jobe O, Zhou Y, Dawson P, Eller MA, Matyas GR, Alving CR.

J Infect Dis. 2018 Oct 5;218(10):1541-1550. doi: 10.1093/infdis/jiy348.

PMID:
29893872
13.

A rapid solution-based method for determining the affinity of heroin hapten-induced antibodies to heroin, its metabolites, and other opioids.

Torres OB, Duval AJ, Sulima A, Antoline JFG, Jacobson AE, Rice KC, Alving CR, Matyas GR.

Anal Bioanal Chem. 2018 Jun;410(16):3885-3903. doi: 10.1007/s00216-018-1060-4. Epub 2018 Apr 19.

14.

Immune response to antigen adsorbed to aluminum hydroxide particles: Effects of co-adsorption of ALF or ALFQ adjuvant to the aluminum-antigen complex.

Beck Z, Torres OB, Matyas GR, Lanar DE, Alving CR.

J Control Release. 2018 Apr 10;275:12-19. doi: 10.1016/j.jconrel.2018.02.006. Epub 2018 Feb 9.

15.

Heroin-HIV-1 (H2) vaccine: induction of dual immunologic effects with a heroin hapten-conjugate and an HIV-1 envelope V2 peptide with liposomal lipid A as an adjuvant.

Torres OB, Matyas GR, Rao M, Peachman KK, Jalah R, Beck Z, Michael NL, Rice KC, Jacobson AE, Alving CR.

NPJ Vaccines. 2017 May 2;2:13. doi: 10.1038/s41541-017-0013-9. eCollection 2017.

16.

A Stable Heroin Analogue That Can Serve as a Vaccine Hapten to Induce Antibodies That Block the Effects of Heroin and Its Metabolites in Rodents and That Cross-React Immunologically with Related Drugs of Abuse.

Sulima A, Jalah R, Antoline JFG, Torres OB, Imler GH, Deschamps JR, Beck Z, Alving CR, Jacobson AE, Rice KC, Matyas GR.

J Med Chem. 2018 Jan 11;61(1):329-343. doi: 10.1021/acs.jmedchem.7b01427. Epub 2017 Dec 29.

17.

Liposomes containing monophosphoryl lipid A and QS-21 serve as an effective adjuvant for soluble circumsporozoite protein malaria vaccine FMP013.

Genito CJ, Beck Z, Phares TW, Kalle F, Limbach KJ, Stefaniak ME, Patterson NB, Bergmann-Leitner ES, Waters NC, Matyas GR, Alving CR, Dutta S.

Vaccine. 2017 Jul 5;35(31):3865-3874. doi: 10.1016/j.vaccine.2017.05.070. Epub 2017 Jun 7.

18.

Development of a self-assembling protein nanoparticle vaccine targeting Plasmodium falciparum Circumsporozoite Protein delivered in three Army Liposome Formulation adjuvants.

Seth L, Bingham Ferlez KM, Kaba SA, Musser DM, Emadi S, Matyas GR, Beck Z, Alving CR, Burkhard P, Lanar DE.

Vaccine. 2017 Oct 4;35(41):5448-5454. doi: 10.1016/j.vaccine.2017.02.040. Epub 2017 Mar 6.

19.

Synthesis of Hapten-Protein Conjugate Vaccines with Reproducible Hapten Densities.

Torres OB, Alving CR, Matyas GR.

Methods Mol Biol. 2016;1403:695-710. doi: 10.1007/978-1-4939-3387-7_39.

PMID:
27076161
20.

Liposomal adjuvants for human vaccines.

Alving CR, Beck Z, Matyas GR, Rao M.

Expert Opin Drug Deliv. 2016 Jun;13(6):807-16. doi: 10.1517/17425247.2016.1151871. Epub 2016 Feb 25. Review.

PMID:
26866300
21.

A simple nonradioactive method for the determination of the binding affinities of antibodies induced by hapten bioconjugates for drugs of abuse.

Torres OB, Antoline JF, Li F, Jalah R, Jacobson AE, Rice KC, Alving CR, Matyas GR.

Anal Bioanal Chem. 2016 Feb;408(4):1191-204. doi: 10.1007/s00216-015-9223-z. Epub 2015 Dec 16.

22.

Differential immune responses to HIV-1 envelope protein induced by liposomal adjuvant formulations containing monophosphoryl lipid A with or without QS21.

Beck Z, Matyas GR, Jalah R, Rao M, Polonis VR, Alving CR.

Vaccine. 2015 Oct 13;33(42):5578-5587. doi: 10.1016/j.vaccine.2015.09.001. Epub 2015 Sep 13.

PMID:
26372857
23.

Comparable Antigenicity and Immunogenicity of Oligomeric Forms of a Novel, Acute HIV-1 Subtype C gp145 Envelope for Use in Preclinical and Clinical Vaccine Research.

Wieczorek L, Krebs SJ, Kalyanaraman V, Whitney S, Tovanabutra S, Moscoso CG, Sanders-Buell E, Williams C, Slike B, Molnar S, Dussupt V, Alam SM, Chenine AL, Tong T, Hill EL, Liao HX, Hoelscher M, Maboko L, Zolla-Pazner S, Haynes BF, Pensiero M, McCutchan F, Malek-Salehi S, Cheng RH, Robb ML, VanCott T, Michael NL, Marovich MA, Alving CR, Matyas GR, Rao M, Polonis VR.

J Virol. 2015 Aug;89(15):7478-93. doi: 10.1128/JVI.00412-15. Epub 2015 May 13.

24.

Efficacy, but not antibody titer or affinity, of a heroin hapten conjugate vaccine correlates with increasing hapten densities on tetanus toxoid, but not on CRM197 carriers.

Jalah R, Torres OB, Mayorov AV, Li F, Antoline JF, Jacobson AE, Rice KC, Deschamps JR, Beck Z, Alving CR, Matyas GR.

Bioconjug Chem. 2015 Jun 17;26(6):1041-53. doi: 10.1021/acs.bioconjchem.5b00085. Epub 2015 Jun 5.

25.

Detection of liposomal cholesterol and monophosphoryl lipid A by QS-21 saponin and Limulus polyphemus amebocyte lysate.

Beck Z, Matyas GR, Alving CR.

Biochim Biophys Acta. 2015 Mar;1848(3):775-80. doi: 10.1016/j.bbamem.2014.12.005. Epub 2014 Dec 12.

26.

Adjuvants for vaccines to drugs of abuse and addiction.

Alving CR, Matyas GR, Torres O, Jalah R, Beck Z.

Vaccine. 2014 Sep 22;32(42):5382-9. doi: 10.1016/j.vaccine.2014.07.085. Epub 2014 Aug 8. Review.

27.

Characterization and optimization of heroin hapten-BSA conjugates: method development for the synthesis of reproducible hapten-based vaccines.

Torres OB, Jalah R, Rice KC, Li F, Antoline JF, Iyer MR, Jacobson AE, Boutaghou MN, Alving CR, Matyas GR.

Anal Bioanal Chem. 2014 Sep;406(24):5927-37. doi: 10.1007/s00216-014-8035-x. Epub 2014 Aug 2.

28.

Synthesis and immunological effects of heroin vaccines.

Li F, Cheng K, Antoline JF, Iyer MR, Matyas GR, Torres OB, Jalah R, Beck Z, Alving CR, Parrish DA, Deschamps JR, Jacobson AE, Rice KC.

Org Biomol Chem. 2014 Oct 7;12(37):7211-32. doi: 10.1039/c4ob01053a.

29.

Facial recognition of heroin vaccine opiates: type 1 cross-reactivities of antibodies induced by hydrolytically stable haptenic surrogates of heroin, 6-acetylmorphine, and morphine.

Matyas GR, Rice KC, Cheng K, Li F, Antoline JF, Iyer MR, Jacobson AE, Mayorov AV, Beck Z, Torres OB, Alving CR.

Vaccine. 2014 Mar 14;32(13):1473-9. doi: 10.1016/j.vaccine.2014.01.028. Epub 2014 Jan 28.

30.

Platelets and erythrocyte-bound platelets bind infectious HIV-1 in plasma of chronically infected patients.

Beck Z, Jagodzinski LL, Eller MA, Thelian D, Matyas GR, Kunz AN, Alving CR.

PLoS One. 2013 Nov 25;8(11):e81002. doi: 10.1371/journal.pone.0081002. eCollection 2013.

31.

Liposomes containing monophosphoryl lipid A: a potent adjuvant system for inducing antibodies to heroin hapten analogs.

Matyas GR, Mayorov AV, Rice KC, Jacobson AE, Cheng K, Iyer MR, Li F, Beck Z, Janda KD, Alving CR.

Vaccine. 2013 Jun 10;31(26):2804-10. doi: 10.1016/j.vaccine.2013.04.027. Epub 2013 Apr 23.

32.

Disruption of the putative vascular leak peptide sequence in the stabilized ricin vaccine candidate RTA1-33/44-198.

Janosi L, Compton JR, Legler PM, Steele KE, Davis JM, Matyas GR, Millard CB.

Toxins (Basel). 2013 Jan 30;5(2):224-48. doi: 10.3390/toxins5020224.

33.

Liposomes containing lipid A: an effective, safe, generic adjuvant system for synthetic vaccines.

Alving CR, Rao M, Steers NJ, Matyas GR, Mayorov AV.

Expert Rev Vaccines. 2012 Jun;11(6):733-44. doi: 10.1586/erv.12.35. Review.

PMID:
22873129
34.

An anti-phosphoinositide-specific monoclonal antibody that neutralizes HIV-1 infection of human monocyte-derived macrophages.

Jobe O, Peachman KK, Matyas GR, Asher LV, Alving CR, Rao M.

Virology. 2012 Sep 1;430(2):110-9. doi: 10.1016/j.virol.2012.04.017. Epub 2012 May 26.

35.

Phase I study of a Neisseria meningitidis liposomal vaccine containing purified outer membrane proteins and detoxified lipooligosaccharide.

Zollinger WD, Babcock JG, Moran EE, Brandt BL, Matyas GR, Wassef NM, Alving CR.

Vaccine. 2012 Jan 17;30(4):712-21. doi: 10.1016/j.vaccine.2011.11.084. Epub 2011 Dec 3.

PMID:
22138211
36.

Anthrax vaccine antigen-adjuvant formulations completely protect New Zealand white rabbits against challenge with Bacillus anthracis Ames strain spores.

Peachman KK, Li Q, Matyas GR, Shivachandra SB, Lovchik J, Lyons RC, Alving CR, Rao VB, Rao M.

Clin Vaccine Immunol. 2012 Jan;19(1):11-6. doi: 10.1128/CVI.05376-11. Epub 2011 Nov 16.

37.
38.

Infection of human peripheral blood mononuclear cells by erythrocyte-bound HIV-1: effects of antibodies and complement.

Beck Z, Brown BK, Matyas GR, Polonis VR, Rao M, Alving CR.

Virology. 2011 Apr 10;412(2):441-7. doi: 10.1016/j.virol.2011.01.037. Epub 2011 Feb 21.

39.

The importance of antibody isotype in HIV-1 virus capture assay and in TZM-bl neutralization.

Peachman KK, Wieczorek L, Matyas GR, Polonis VR, Alving CR, Rao M.

Viral Immunol. 2010 Dec;23(6):627-32. doi: 10.1089/vim.2010.0061.

PMID:
21142448
40.

Highly effective generic adjuvant systems for orphan or poverty-related vaccines.

Rao M, Peachman KK, Li Q, Matyas GR, Shivachandra SB, Borschel R, Morthole VI, Fernandez-Prada C, Alving CR, Rao VB.

Vaccine. 2011 Jan 29;29(5):873-7. doi: 10.1016/j.vaccine.2010.11.049. Epub 2010 Nov 27.

41.

Inhibition of HIV-1 infection of peripheral blood mononuclear cells by a monoclonal antibody that binds to phosphoinositides and induces secretion of β-chemokines.

Matyas GR, Wieczorek L, Bansal D, Chenine AL, Sanders-Buell E, Tovanabutra S, Kim JH, Polonis V, Alving CR.

Biochem Biophys Res Commun. 2010 Nov 26;402(4):808-12. doi: 10.1016/j.bbrc.2010.10.124. Epub 2010 Oct 30.

PMID:
21040700
42.

Human erythrocytes selectively bind and enrich infectious HIV-1 virions.

Beck Z, Brown BK, Wieczorek L, Peachman KK, Matyas GR, Polonis VR, Rao M, Alving CR.

PLoS One. 2009 Dec 14;4(12):e8297. doi: 10.1371/journal.pone.0008297.

43.

Neutralizing antibodies induced by liposomal HIV-1 glycoprotein 41 peptide simultaneously bind to both the 2F5 or 4E10 epitope and lipid epitopes.

Matyas GR, Wieczorek L, Beck Z, Ochsenbauer-Jambor C, Kappes JC, Michael NL, Polonis VR, Alving CR.

AIDS. 2009 Oct 23;23(16):2069-77. doi: 10.1097/QAD.0b013e32832faea5.

PMID:
19710597
44.

Antibodies to squalene in US Navy Persian Gulf War veterans with chronic multisymptom illness.

Phillips CJ, Matyas GR, Hansen CJ, Alving CR, Smith TC, Ryan MA.

Vaccine. 2009 Jun 12;27(29):3921-6. doi: 10.1016/j.vaccine.2009.03.091. Epub 2009 May 3.

PMID:
19379786
45.

Anthrax LFn-PA Hybrid Antigens: Biochemistry, Immunogenicity, and Protection Against Lethal Ames Spore Challenge in Rabbits.

Li Q, Peachman KK, Sower L, Leppla SH, Shivachandra SB, Matyas GR, Peterson JW, Alving CR, Rao M, Rao VB.

Open Vaccine J. 2009;2:92-99.

46.

Lipid binding properties of 4E10, 2F5, and WR304 monoclonal antibodies that neutralize HIV-1.

Matyas GR, Beck Z, Karasavvas N, Alving CR.

Biochim Biophys Acta. 2009 Mar;1788(3):660-5. doi: 10.1016/j.bbamem.2008.11.015. Epub 2008 Dec 3.

47.

Membrane-specific antibodies induced by liposomes can simultaneously bind to HIV-1 protein, peptide, and membrane lipid epitopes.

Beck Z, Karasavvas N, Matyas GR, Alving CR.

J Drug Target. 2008 Aug;16(7):535-42. doi: 10.1080/10611860802228517.

PMID:
18686123
48.

Antibodies induced by liposomal protein exhibit dual binding to protein and lipid epitopes.

Karasavvas N, Beck Z, Tong J, Matyas GR, Rao M, McCutchan FE, Michael NL, Alving CR.

Biochem Biophys Res Commun. 2008 Feb 22;366(4):982-7. Epub 2007 Dec 26.

PMID:
18088597
49.

Calcium modulation of monoclonal antibody binding to phosphatidylinositol phosphate.

Beck Z, Karasavvas N, Tong J, Matyas GR, Rao M, Alving CR.

Biochem Biophys Res Commun. 2007 Mar 16;354(3):747-51. Epub 2007 Jan 16.

PMID:
17257584
50.

Monoclonal antibodies to phosphatidylinositol phosphate neutralize human immunodeficiency virus type 1: role of phosphate-binding subsites.

Brown BK, Karasavvas N, Beck Z, Matyas GR, Birx DL, Polonis VR, Alving CR.

J Virol. 2007 Feb;81(4):2087-91. Epub 2006 Dec 6.

Supplemental Content

Loading ...
Support Center